Literature DB >> 6330021

Concentrations of cefotaxime and the desacetyl metabolite in serum and CSF of patients with meningitis.

G Humbert, A Leroy, S R Nair, C E Cherubin.   

Abstract

Thirty-two cases of meningitis (20 caused by Gram-positive or -negative cocci, 7 by Gram-negative bacilli or listeria, and 5 with aseptic meningitis) received cefotaxime, 2 g 8-hourly, in addition to routine therapy. The concentrations of cefotaxime and its desacetyl metabolite in serum and CSF were determined by a high pressure liquid chromotography. Mean concentration of cefotaxime in CSF ranged from 0.8 mg/l (aseptic meningitis), to 6.4 mg/l (Gram-negative and listeria meningitis), and from 0.5 to 5.4 mg/l for the metabolite. The concentrations of both cefotaxime and the derivative demonstrated a correlation with the degree of inflammation (i.e., cell count and protein concentration) and were higher at 3 h after an infusion of antibiotic than at one and two hours. The concentration showed no marked decline on day 10 when signs of inflammation had largely resolved. The concentrations of both the parent compound and the metabolite 3 h after the infusion suggest that, considering the activity and half life of both the dosing might be spaced at 6-8 h intervals.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6330021     DOI: 10.1093/jac/13.5.487

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

1.  Microdialysis study of cefotaxime cerebral distribution in patients with acute brain injury.

Authors:  Claire Dahyot-Fizelier; Denis Frasca; Nicolas Grégoire; Christophe Adier; Olivier Mimoz; Bertrand Debaene; William Couet; Sandrine Marchand
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

Review 2.  Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid.

Authors:  I Lutsar; I R Friedland
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

3.  Penetration of Cefotaxime into Cerebrospinal Fluid in Neonates and Young Infants.

Authors:  Xing-Kai Chen; Hai-Yan Shi; Stephanie Leroux; Hai-Yan Xu; Yue Zhou; Yi Zheng; Xin Huang; Yan Li; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 4.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 5.  Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.

Authors:  Roland Nau; Fritz Sörgel; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

6.  Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections.

Authors:  Ravina Kullar; Judy N Chin; David J Edwards; Dennis Parker; William M Coplin; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2011-04-18       Impact factor: 5.191

7.  Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges.

Authors:  R Nau; H W Prange; P Muth; G Mahr; S Menck; H Kolenda; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

8.  Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis.

Authors:  J M Trang; R F Jacobs; G L Kearns; A L Brown; T G Wells; F L Underwood; R B Kluza
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

9.  Criteria for testing the susceptibility of Streptococcus pneumoniae to cefotaxime and its desacetyl metabolite using 1 microgram or 30 micrograms cefotaxime disks.

Authors:  A L Barry; S D Brown; W J Novick
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-08       Impact factor: 3.267

Review 10.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.